Compare Medpace Holdings Inc (MEDP) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs ON Holding AG — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while ON Holding AG trades at $35.09 (market cap $11.38B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and ON Holding AG for 22 Days on average.
| MEDP | ONON | |
|---|---|---|
Market Cap | $16.82B | $11.38B |
Volume | 223,093 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $50.63 |
52-Week Low | $393.42 | $26.76 |
Typical Hold Time | 14 Days | 22 Days |
Enterprise Value | $16.44B | $10.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
ONON trades at $34.04, up 2.47% today, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.44 exceeding the $0.4203 estimate. Revenue reached $3.01B in 2025, with net income of $203.70M, and profitability metrics like a 64.82% gross margin and 23.95% ROE indicate operational strength. Recent news highlights a $1 billion share buyback plan and ambitious 2029 targets.
The outlook is positive, supported by analyst consensus with a $42.26 price target and 74% buy ratings. Key opportunities include direct-to-consumer growth and expansion into new sports categories, while risks involve competitive pressures and execution of long-term goals amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
